Third Pole Therapeutics
MA - WalthamBiotechnology
Focus: Third Pole Therapeutics is a pre-revenue biotech company developing an inhaled nitric oxide delivery system focused on pulmonary hypertension treatment. The company operates as a specialized respiratory therapeutics player based in Waltham, MA with minimal disclosed scale.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Total Funding
$25M
Open Jobs
2
Should You Work at Third Pole Therapeutics?
AI assessmentThird Pole represents a high-risk, pre-clinical opportunity suitable only for risk-tolerant candidates seeking ground-floor equity upside in a narrow specialty; viability remains unproven.
Why Work Here
- Focused technology platform in inhaled NO delivery addresses unmet need in pulmonary hypertension with potentially differentiated route of administration
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Inhaled Nitric Oxide
Hypertension, PulmonaryClinical Trials (1)
NCT05867914Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
N/AHelp build intelligence for Third Pole Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.